CLOUDR (09955) announced that the company has recently entered into a service cooperation agreement with JD HEALTH (06618). The collaboration aims to expand online sales and service channels for Remifemin® and other P2M pipeline products, providing patients with more convenient medication purchasing experiences and professional full-cycle health management services. As China's largest pharmaceutical e-commerce platform, JD HEALTH boasts a vast user base and extensive platform resources. Meanwhile, CLOUDR, a leading chronic disease management platform in China, possesses a unique product pipeline and expertise in patient-doctor management. This partnership represents a powerful alliance that will efficiently promote high-quality and cost-effective pharmaceutical products.